Post

Dr.Toxic🚩
Dr.Toxic🚩
A lockup expiry can reveal more about positioning than fundamentals. SpaceX rising about 6% as up to 911.5M shares became eligible for sale suggests the immediate supply risk may have been more anticipated than feared. Still, the first post-IPO report leaves a harder test ahead: roughly $7.8B in revenue, up about 90% YoY, alongside a $541M net loss and concern over higher AI capex. My read is that the rebound buys management time, not immunity. From here, guidance, margins and cash discipline must turn the AI-space infrastructure thesis into measurable operating progress. Not advice, just analysis. #SpaceXUnlockRebound #OKXOrbit#AIMemoryBullTest #FedHawksVsWeakJobs #SpaceXUnlockRebound

Disclaimer: i contenuti di OKX Orbit sono forniti solo a scopo informativo. Scopri di più

Risposte

Ancora nessun commento. Rispondi prima di tutti!